(Washington, D.C.) — The Pharmaceutical Supply and Payment Chain Coalition issued the following statement in response to the Administration’s 100-day review of the actions needed to address vulnerabilities in our nation’s pharmaceutical supply chain and what measures need to be taken in order
Welcome to the Pharmacy Benefit Brief. This brief is your monthly snapshot of news from America’s prescription drug supply chain including pharmacy benefit managers, independent pharmacies, and drug manufacturers. Getting the Ball Rolling… The idea that biosimilars,
Pharmacy Benefit Companies Ready to Work with Policymakers on Solutions to Build a More Competitive, Sustainable, and Affordable Prescription Drug Marketplace
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement on today’s remarks by Food and Drug Administration Commissioner Scott Gottlieb, specifically those appearing to reference drug manufacturer abuses of risk evaluation and mitigation strategies (REMS) that
New Research Paper Demonstrates Declining Biosimilars Prices and Increasing Health Plan Coverage (Washington, D.C.) — Pharmacy benefit managers, PBMs, support the proliferation and use of biosimilars. A robust biosimilar market will increase competition for biologic drugs and provide added choice
A recent article (“The Corporate Scam that Even Trump Opposes: PBMs”) attacks the one industry that is both reducing prescription drug costs and improving quality: pharmacy benefit managers (PBMs). The White House fiscal year 2019 budget included many cost-saving items PBMs have
(Washington, D.C.) — New data from the National Council for Prescription Drug Programs (NCPDP) database, highlighted today by the Pharmaceutical Care Management Association (PCMA), shows that the independent retail pharmacy market in the United States is stable. Over the last 10 years,
(Washington, D.C.) —Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on the Senate Judiciary Committee hearing, “Intellectual Property and the Price of Prescription Drugs: Balancing Innovation and Competition:” “We applaud the Senate Judiciary Committee
(Washington, D.C.) —Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott released the following statement on bipartisan legislation introduced by Sens. Bill Cassidy (R-LA) and Dick Durbin (D-IL), the “Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act:”
©2024 PCMA. All Rights Reserved.
